🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

From Alex Philippidis at Genetic Engineering & Biotechnology News, a feature on the long-term research collaboration that led to our investigational drug prosetin, and our development plans in #ALS. Read more: genengnews.com/topics/drug-di…

ProJenX is excited announce the formation of our Scientific Advisory Board. This world-class group of researchers and clinicians will guide our efforts to advance prosetin in ALS and other neurodegenerative diseases. Read more here: projenx.com/scientific-adv…

Recently, the U.S. FDA has lifted its partial clinical hold on ProJenX’s hybrid phase 1 study assessing its investigational MAP4 kinase (MAP4K) inhibitor prosetin as a potential treatment for patients with #ALS. Columbia University Jinsy Andrews, MD neurologylive.com/view/fda-remov…

Tune in next week for an update on the Phase 1 study of prosetin with Erin Fleming, our VP of R&D!

“ALS-specific biology and chemistry takes time, but careful preclinical studies are essential for more rational therapeutic candidates.” A great thought presented by Erin Fleming, Vice President, Research and Development at ProJenX during the Built for Speed: Strategies to